These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36581261)

  • 21. Categorization framework to aid exposure assessment of nanomaterials in consumer products.
    Hansen SF; Michelson ES; Kamper A; Borling P; Stuer-Lauridsen F; Baun A
    Ecotoxicology; 2008 Jul; 17(5):438-47. PubMed ID: 18454314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measuring nanoparticles size distribution in food and consumer products: a review.
    Calzolai L; Gilliland D; Rossi F
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2012 Aug; 29(8):1183-93. PubMed ID: 22725833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanomaterial Drug Products: Manufacturing and Analytical Perspectives.
    Sayes CM; Aquino GV; Hickey AJ
    AAPS J; 2017 Jan; 19(1):18-25. PubMed ID: 27822601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery.
    Fan Y; Marioli M; Zhang K
    J Pharm Biomed Anal; 2021 Jan; 192():113642. PubMed ID: 33011580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of information in nanomaterial safety data sheets and development of international standard for guidance on preparation of nanomaterial safety data sheets.
    Lee JH; Kuk WK; Kwon M; Lee JH; Lee KS; Yu IJ
    Nanotoxicology; 2013 May; 7(3):338-45. PubMed ID: 22263625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop.
    Warheit DB; Borm PJ; Hennes C; Lademann J
    Inhal Toxicol; 2007 Jun; 19(8):631-43. PubMed ID: 17510836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
    Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
    Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System.
    Lee GH; Ahn KH; Yu IJ
    J Vis Exp; 2016 Nov; (117):. PubMed ID: 27911389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoamorphous drug products - Design and development.
    Jog R; Burgess DJ
    Int J Pharm; 2018 Dec; 553(1-2):238-260. PubMed ID: 30359685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the Quality by Design method.
    Kovács A; Berkó S; Csányi E; Csóka I
    Eur J Pharm Sci; 2017 Mar; 99():246-257. PubMed ID: 28012940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells.
    Lujan H; Griffin WC; Taube JH; Sayes CM
    Int J Nanomedicine; 2019; 14():5159-5173. PubMed ID: 31371954
    [No Abstract]   [Full Text] [Related]  

  • 33. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery.
    Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C
    Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives.
    Foulkes R; Man E; Thind J; Yeung S; Joy A; Hoskins C
    Biomater Sci; 2020 Sep; 8(17):4653-4664. PubMed ID: 32672255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms.
    Nupur N; Joshi S; Gulliarme D; Rathore AS
    Front Bioeng Biotechnol; 2022; 10():832059. PubMed ID: 35223794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomaterials in consumer products: a challenging analytical problem.
    Contado C
    Front Chem; 2015; 3():48. PubMed ID: 26301216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
    Tyner K; Sadrieh N
    Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities.
    Tyner KM; Zheng N; Choi S; Xu X; Zou P; Jiang W; Guo C; Cruz CN
    AAPS J; 2017 Jul; 19(4):1071-1083. PubMed ID: 28421428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of different analytical methods for the characterization of non-spherical micro- and nanoparticles.
    Mathaes R; Winter G; Engert J; Besheer A
    Int J Pharm; 2013 Sep; 453(2):620-9. PubMed ID: 23727141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanosize drug delivery system.
    Mukherjee B
    Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.